NCT04521153View on ClinicalTrials.gov

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

March 1, 2026

Conditions
Hepatocellular CarcinomaImmunotherapyMolecular Targeted Therapy
Interventions
DRUG

Camrelizumab

Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery

DRUG

Apatinib Mesylate

Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery

PROCEDURE

Radical surgery

Radical surgery

Trial Locations (1)

200032

180 Fenglin Road, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER